公开(公告)号：WO2023088073A1

公开(公告)日：2023-05-25

申请号：PCT/CN2022/128319

申请日：2022-10-28

申请人： 山东省科学院生物研究所

发明人： 张轩铭 ,  刘可春 ,  靳梦 ,  李晓彬 ,  张云 ,  屠鹏飞 ,  张姗姗 ,  夏青 ,  王利振 ,  盛文龙 ,  李培海

IPC分类号： C07K1/34 ,  A61P39/06 ,  C07K1/30 ,  C12P21/06 ,  A61K38/01 ,  A61P9/12 ,  A61P3/10 ,  A23L33/18 ,  A61K31/7036 ,  C07K1/36 ,  A61Q19/08 ,  A61P37/02 ,  A61Q19/00 ,  A61P29/00 ,  A61K8/64

摘要： 本发明涉及一种多功能西洋参水解肽及其制备方法和应用，本申请提供的西洋参水解肽中活性肽含量高达85％以上，所述活性肽的分子量范围

公开(公告)号：WO2023079278A1

公开(公告)日：2023-05-11

申请号：PCT/GB2022/052764

申请日：2022-11-03

申请人： DUCENTIS BIOTHERAPEUTICS LIMITED

发明人： ASHFIELD, Rebecca ,  HUXLEY, Philip

IPC分类号： C07K14/705 ,  A61K38/00 ,  A61P37/02

摘要： The invention relates generally to mutant CD200 proteins which bind with greater affinity to the CD200 receptor than wild-type CD200, in particular the invention relates to a mutated CD200 protein comprising specific mutations at amino acid residue position 130 and/or 131. This invention also relates to a fusion protein comprising the protein as defined herein fused to a non-CD200 protein portion directly or via an optional linker portion, a pharmaceutical composition comprising the protein as defined herein and uses thereof.

公开(公告)号：WO2023077061A1

公开(公告)日：2023-05-04

申请号：PCT/US2022/078863

申请日：2022-10-28

申请人： WEINER, David ,  PURWAR, Mansi ,  KULKARNI, Abhijeet ,  PARK, Daniel ,  BORDOLOI, Devivasha ,  BHOJNAGARWALA, Pratik

发明人： WEINER, David ,  PURWAR, Mansi ,  KULKARNI, Abhijeet ,  PARK, Daniel ,  BORDOLOI, Devivasha ,  BHOJNAGARWALA, Pratik

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  A61P37/02 ,  C07K16/10

摘要： An advance on monoclonal technology is the development of bispecific T cell engagers (BITE) which combine the specificity of monoclonal antibodies with the cytotoxic potential of T cells. Disclosed herein are compositions comprising a recombinant nucleic acid sequence encoding a bispecific anti-HIV natural killer engager, a fragment thereof, a variant thereof, or a combination thereof, and methods of use thereof.

公开(公告)号：WO2023073005A1

公开(公告)日：2023-05-04

申请号：PCT/EP2022/079912

申请日：2022-10-26

申请人： CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) ,  UNIVERSIDAD DE SEVILLA ,  ACADEMIA SINICA

发明人： GARCÍA FERNÁNDEZ, José Manuel ,  ORTIZ MELLET, Carmen ,  GONZÁLEZ CUESTA, Manuel ,  SÁNCHEZ FERNÁNDEZ, Elena Matilde ,  CHANG, Ya-Jen ,  LAI, Alan Chuan-Ying

IPC分类号： C07D498/04 ,  A61K31/4355 ,  A61K31/7056 ,  A61P37/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P37/08 ,  A61P29/00 ,  A61P1/00 ,  A61P1/16 ,  A61P3/00 ,  A61P31/00 ,  A61P11/00 ,  A61P11/06

摘要： The invention relates to a 5-aminohexahydro-6,7,8-trihydroxy-3H- oxazolo[3,4-a]pyridin-3-one (i.e. 2,3,4-trihydroxy-5N,6O- oxomethylidene-nojirimycin-l-amine) glycolipid mimetic derivative of formula (I) acting as antagonists or agonist of the TLR4 for the treatment and/ or prevention of an immune disease such as e.g. acute inflammation, chronic disease allergy, the Metabolic Syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), immune mediated hepatitis, an autoimmune disease, graft rejection pathology, inflammatory bowel disease, atherosclerosis and airway hyperactivity, such as e.g. asthma and allergic rhinitis. An exemplary compound is e.g. example 1, compound (1).

公开(公告)号：WO2023072850A1

公开(公告)日：2023-05-04

申请号：PCT/EP2022/079632

申请日：2022-10-24

申请人： ELLENNBE GMBH

发明人： NEUMANN, Lydia Ellen

IPC分类号： A61K38/20 ,  A61K38/21 ,  A61K35/17 ,  A61P19/02 ,  A61F7/02 ,  A61K9/06 ,  A61F7/08 ,  A61K31/455 ,  A61P29/00 ,  A61P37/02

摘要： The invention relates to pharmaceutical compositions comprising immunomodulatory substances. Particularly, the invention relates to a pharmaceutical composition comprising an IFN-γ-like acting substance, IL-4-like acting substance, BDNF-like acting substance and/or IL-2-like acting substance, wherein the pharmaceutical composition is suitable to deliver the IFN-γ-like acting substance, IL-4- like acting substance, BDNF-like acting substance and/or IL-2- like acting substance to a subject in low amounts. The invention further relates to a pharmaceutical composition comprising an IFN-γ-like acting substance, IL-4-like acting substance, BDNF-like acting substance and/or IL-2-like acting substance in low concentrations. The pharmaceutical compositions are particularly useful in treating and/or preventing an inflammatory disease, immunological disease and/or autoimmunological disease in a subject.

公开(公告)号：WO2023069418A2

公开(公告)日：2023-04-27

申请号：PCT/US2022/046998

申请日：2022-10-18

申请人： OBSIDIAN THERAPEUTICS, INC.

发明人： SETHI, Dhruv ,  SMITH, Sean ,  OLS, Michelle ,  SUN, Dexue ,  LI, Dan Jun ,  TER MEULEN, Jan ,  SCHEBESTA, Michael

IPC分类号： A61P37/02 ,  C07K14/725 ,  C12N9/06 ,  C07K14/72 ,  C07K14/705 ,  C12N9/88 ,  C07K14/54 ,  C07K14/55 ,  C07K14/555

摘要： Provided herein are engineered, regulatable polypeptides comprising a payload and a modulation hub with at least two drug responsive domains (DRD), wherein the modulation hub is operably linked to the payload and wherein the at least two DRDs are responsive to a ligand. Also provided are engineered monomers comprising an oligomerization domain and a payload, a DRD or both a payload and DRD, wherein the monomers are configured to assemble into oligomers by way of the oligomerization domain and the oligomers comprise at least one payload operably linked to a modulation hub. The abundance, availability and/or biological activity of the payload is regulated by interaction of the one or more DRDs and an effective amount of ligand.

公开(公告)号：WO2023067577A1

公开(公告)日：2023-04-27

申请号：PCT/IB2022/060159

申请日：2022-10-21

申请人： UNIVERSITY HEALTH NETWORK

发明人： HIRANO, Naoto ,  MURATA, Kenji ,  LY, Dalam ,  SAIJO, Hiroshi ,  MATSUNAGA, Yukiko

IPC分类号： C07K14/74 ,  A61K31/7088 ,  A61K38/17 ,  A61K38/46 ,  A61P35/00 ,  A61P37/02 ,  C12N15/10 ,  C12N15/12

摘要： The present disclosure is directed to methods of modifying an HLA-binding pocket in an HLA molecule in a subject. Some aspects are directed to HLA molecules comprising a modified HLA-binding pocket, where the HLA molecule has increased affinity for a peptide, e.g., an antigen. Other aspects are directed to compositions comprising the same and methods of using the same.

公开(公告)号：WO2023063242A1

公开(公告)日：2023-04-20

申请号：PCT/JP2022/037560

申请日：2022-10-07

申请人： タグシクス・バイオ株式会社

发明人： 原田　香織 ,  堀　美幸

IPC分类号： C12N15/115 ,  A61K31/711 ,  A61K47/55 ,  A61P1/00 ,  A61P1/16 ,  A61P3/10 ,  A61P9/00 ,  A61P13/10 ,  A61P15/00 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14 ,  A61P19/00 ,  A61P19/02 ,  A61P25/28 ,  A61P27/02 ,  A61P27/04 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  C07K14/57

摘要： ＩＦＮ－γを選択的に阻害することができ、生物学的汚染のおそれが無く、室温での保存が可能である自己免疫性疾患治療薬を提供することを目的とする。配列番号１から３のいずれかに記載の塩基配列を有し、ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを有効成分として含有する自己免疫性疾患治療薬を提供する。別の態様として、配列番号１から３のいずれかに記載の塩基配列を有し、ＩＦＮ－γへ選択的に結合することで自己免疫性疾患治療効果を有するＤＮＡオリゴヌクレオチドを提供する。

公开(公告)号：WO2023059769A1

公开(公告)日：2023-04-13

申请号：PCT/US2022/045853

申请日：2022-10-06

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： LUKACS, Nicholas, W. ,  ELESELA, Srikanth ,  HOGAN, Simon

IPC分类号： A61P37/02 ,  A61K39/35 ,  A61K39/395

摘要： The disclosure is directed compositions comprising antigen-specific IgA immune complexes and methods of using the compositions to induce immune tolerance against allergens in a subject who has an established Th2 polarized immune response at one or more mucosal sites prior to administering the composition.

公开(公告)号：WO2023045818A1

公开(公告)日：2023-03-30

申请号：PCT/CN2022/118928

申请日：2022-09-15

申请人： 张国华

发明人： 张国华 ZHANG, Guohua

IPC分类号： A61K31/496 ,  A61P17/00 ,  A61P31/12 ,  A61P31/04 ,  A61P31/10 ,  A61P33/00 ,  A61P29/00 ,  A61P37/08 ,  A61P37/02 ,  A61P35/00 ,  A61P17/02 ,  A61P17/06

摘要： 本发明公开了尼达尼布治疗新生血管形成的皮肤疾病的组合物和方法，其包括尼达尼布通过添加辅料制备成的药剂，以局部给药能够加快皮肤愈合并恢复正常。将尼达尼布用于临床治疗新生血管形成的皮肤疾病，帮助患者尽快恢复，并使皮肤尽可能保持原状。